Cours Diaxonhit Euronext Paris
Actions
FR0004054427
Recherche biotechnologique et médicale
CA 2023 * | 131 M 140 M 128 M | CA 2024 * | 138 M 148 M 135 M | Capitalisation | 146 M 156 M 143 M |
---|---|---|---|---|---|
Résultat net 2023 * | 6 M 6,43 M 5,87 M | Résultat net 2024 * | 9 M 9,64 M 8,8 M | VE / CA 2023 * | 1,19 x |
Dette nette 2023 * | 8,8 M 9,42 M 8,61 M | Trésorerie nette 2024 * | 9,9 M 10,6 M 9,68 M | VE / CA 2024 * | 0,99 x |
PER 2023 * |
33,2
x | PER 2024 * |
15
x | Employés | - |
Rendement 2023 * |
-
| Rendement 2024 * |
-
| Flottant | 59,14% |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director of Finance/CFO | 43 | 01/10/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19/06/17 |
Director/Board Member | 68 | 04/11/09 | |
Director/Board Member | 67 | 15/06/17 |
Varia. 1 janv. | Capi. | |
---|---|---|
+1,51% | 42,75 Md | |
+49,22% | 41,61 Md | |
+8,57% | 41,34 Md | |
-12,36% | 26,59 Md | |
+8,92% | 25,49 Md | |
-25,13% | 18,12 Md | |
+29,17% | 12,24 Md | |
-3,12% | 11,76 Md | |
+6,35% | 11 Md |